A study of ALN-5288 for Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Alzheimer's disease, confirmed by a spinal tap or a brain scan showing amyloid buildup within the last 7 years
- You must have mild cognitive impairment or dementia caused by Alzheimer's
- You must not have another type of dementia
- You must have normal liver function, kidney function, and blood pressure
- You must not have uncontrolled psychiatric conditions or a history of seizures in the past 6 months
- You must not have certain infections like HIV, hepatitis B or C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests an experimental drug, DNL628, to see if it is safe and how it affects people with early Alzheimer's disease. It may help slow the disease by targeting a specific process in the brain.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.